Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 3/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.52 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15617638 | 0.88 | METAP1 (0.70) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL29130805 | 0.87 | METAP1 (0.68) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL30715899 | 0.87 | METAP1 (0.68) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL2424817 | 0.84 | METAP1 (0.65) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL14306761 | 0.84 | METAP1 (0.72) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL29130764 | 0.83 | METAP1 (0.64) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL5362542 | 0.82 | METAP1 (0.62) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL8596909 | 0.82 | METAP1 (0.65) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL6272399 | 0.82 | METAP1 (0.65) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL8874844 | 0.82 | METAP1 (0.65) | METAP1CYP19A1CYP24A1CYP26A1CYP27A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1819656-A2 | SYNTHESIS OF 1,5-DISTRIBUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1809594-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7151196-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2006050399-A2 | SYNTHESIS OF 1,5-DISUBSTITUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006050402-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094779-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-05-04 | — | — | US | disclosed |
| EP-1257264-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | disclosed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027840-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | METAP1 4217/4885CYP19A1 8/4885CYP24A1 310/4885 |
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | METAP1 4217/4885CYP19A1 8/4885CYP24A1 310/4885 |
| US-20060094779-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | METAP1 3641/4885CYP19A1 44/4885CYP24A1 341/4885 |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | ESR1, GPER1, CYP19A1 | METAP1 4773/4885CYP19A1 3/4885CYP24A1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.